Anand Patel to Middle Aged
This is a "connection" page, showing publications Anand Patel has written about Middle Aged.
Connection Strength
0.496
-
Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia. Blood Adv. 2024 09 10; 8(17):4647-4650.
Score: 0.062
-
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024 07 09; 8(13):3468-3477.
Score: 0.062
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
Score: 0.060
-
Paraneoplastic Thrombocytopenia. Am J Med. 2021 08; 134(8):976-979.
Score: 0.049
-
Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449.
Score: 0.048
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.046
-
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
Score: 0.016
-
Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov 07; 144(19):2033-2044.
Score: 0.016
-
Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024 11 01; 109(11):3533-3542.
Score: 0.016
-
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 Dec; 99(12):2388-2391.
Score: 0.016
-
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
Score: 0.015
-
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
Score: 0.015
-
Transfusion management and hemoglobin-based oxygen carrier treatment in a patient with anti-Rh17 antibody. Transfusion. 2024 Jun; 64(6):1161-1166.
Score: 0.015
-
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023 04; 37(4):799-806.
Score: 0.014
-
Impact of race on outcomes in intermediate-risk acute myeloid leukemia. Cancer Causes Control. 2021 Jul; 32(7):705-712.
Score: 0.012
-
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 04 01; 127(7):1039-1048.
Score: 0.012
-
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020 05 26; 4(10):2308-2316.
Score: 0.012
-
FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight. 2018 08 09; 3(15).
Score: 0.010